Stroke prevention in atrial fibrillation in older adults: Existing knowledge gaps and areas for innovation: A summary of an American federation for aging research seminar

Journal of the American Geriatrics Society

Volumn 61, Issue 10, 2013, Pages 1798-1803

  Lubitz, Steven A ^a   Bauer, Kenneth A ^b,c   Benjamin, Emelia J ^d,e   Besdine, Richard W ^f   Forman, Daniel E ^g,h,i   Gurol, Mahmut E ^a   Reddy, Vivek Y ^j   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e BOSTON UNIVERSITY   (United States)

^f BROWN UNIVERSITY   (United States)

^g Geriatrics Research Education and Clinical Center   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

atrial fibrillation; elderly; prevention; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDOXABAN; PLACEBO; RIVAROXABAN; WARFARIN;

AGING; ARTICLE; BRAIN ISCHEMIA; GENETIC SUSCEPTIBILITY; GERIATRIC CARE; HEART ATRIUM FIBRILLATION; HUMAN; MORBIDITY; PREVALENCE; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

ATRIAL FIBRILLATION; ELDERLY; PREVENTION; STROKE;

AGED; AGING; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMEDICAL RESEARCH; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PREVALENCE; RISK FACTORS; SOCIETIES, MEDICAL; STROKE; UNITED STATES;

EID: 84885633973     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12456     Document Type: Article

References (34)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012; 125: e2-e220.
3. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
4. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: Data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-398.
5. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011; 4: 313-320.
6. Forman DE, Rich MW, Alexander KP, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol 2011; 57: 1801-1810.
7. Lakatta EG, Levy D,. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: A "set up" for vascular disease. Circulation 2003; 107: 139-146.
8. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 2007; 69: 546-554.
9. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e269-e367.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
11. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002; 288: 2441-2448.
12. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
13. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46.
14. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5: 615-621.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
17. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
18. Katsnelson M, Sacco RL, Moscucci M,. Progress for stroke prevention with atrial fibrillation: Emergence of alternative oral anticoagulants. Circulation 2012; 125: 1577-1583.
19. Administration USFAD. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate) [on-line]. Available at http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820. htm Accessed February 1, 2013.
20. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046.
21. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet 2009; 373: 739-745.
22. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: The CHARGE-AF Consortium. J Am Heart Assoc 2013; 2: e000102.
23. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet 2009; 374: 525-533.
24. Khatib R, Joseph P, Briel M, et al. Blockade of the renin-angiotensin- aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials. Int J Cardiol 2013; 165: 17-24.
25. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010; 304: 2263-2269.
26. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012; 44: 670-675.
27. Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012; 44: 328-333.
28. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
29. Gurol ME, Greenberg SM,. Management of intracerebral hemorrhage. Curr Atheroscler Rep 2008; 10: 324-331.
30. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol 2009; 8: 165-174.
31. Verbeek MM, Kremer BP, Rikkert MO, et al. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009; 66: 245-249.
32. Reynolds MR, Gunnarsson CL, Hunter TD, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: Results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes 2012; 5: 171-181.
33. Santangeli P, Biase LD, Mohanty P, et al. Catheter ablation of atrial fibrillation in octogenarians: Safety and outcomes. J Cardiovasc Electrophysiol 2012; 23: 687-693.
34. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009; 374: 534-542.